Related Experiment Video
Updated: Sep 20, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Approaches to repurposing reverse transcriptase antivirals in cancer
Richard Head1, Saiful Islam1, Jennifer H Martin2
1Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Abstract:
This review highlights the role of reverse transcriptase (RT) inhibition in cellular regulation associated with non-terminal repeat retrotransposons and endogenous retroviruses. Based on their pleiotropic characteristics, RT inhibitors (RTIs) are discussed as potential anticancer agents. Both the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) display cytotoxicity in cancer cells which are likely mediated by endogenous RT inhibition and not necessarily by differing molecular structures. Three features of RTIs are evident in inducing cytotoxicity in cancer cells. Firstly, NRTIs and NNRTIs induce cell cycle arrest. Secondly, they suppress transposable elements, inhibit long interspersed nuclear elements (LINE)-1, with RTI key in cytotoxicity in cancer cells. Thirdly, the cyclic GMP-AMP-synthase-stimulator of interferon genes (cGAS-STING) pathway can be activated by LINE-1-derived cytoplasmic DNA with promotion of p21-dependent cell cycle arrest and cell-mediated immune response. This suggests that RTIs induce DNA strand breaks with incomplete retrotransposition, initiate cell cycle arrest and an immune response. Additionally, poly (ADP-ribose) polymerase 1 and 2 (PARP1, PARP2) and its relationship with DNA methylation is highlighted in the context of LINE-1 retrotransposition. There is a need to examine the relationship between PARP1, PARP2 and mutated BRCA proteins in normal and abnormal LINE-1 retrotransposition. This review explores how efavirenz and related RT inhibitors suppress endogenous reverse transcriptase, providing a basis for preclinical evaluation of RT inhibitors as potential repurposed drugs for cancer treatment.
Insights
Reverse transcriptase inhibitors (RTIs) show anticancer potential by inducing cancer cell death through cell cycle arrest and immune response activation. These drugs suppress transposable elements like LINE-1, offering a new avenue for cancer treatment.
Area of Science:
- Molecular Biology
- Virology
- Oncology
Background:
- Cellular regulation involves non-terminal repeat retrotransposons and endogenous retroviruses.
- Reverse transcriptase (RT) plays a key role in these processes.
- RT inhibitors (RTIs) are explored for their potential in cancer therapy.
Purpose of the Study:
- To review the role of RT inhibition in cellular regulation.
- To discuss RT inhibitors (RTIs) as potential anticancer agents.
- To explore the mechanisms by which RTIs induce cytotoxicity in cancer cells.
Main Methods:
- Review of existing literature on RT inhibitors and their effects on cancer cells.
- Analysis of the mechanisms of cytotoxicity induced by nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).
- Investigation into the role of LINE-1 elements and the cGAS-STING pathway in RTI-mediated effects.
Main Results:
- RTIs, including NRTIs and NNRTIs, exhibit cytotoxicity in cancer cells, likely via endogenous RT inhibition.
- RTIs induce cell cycle arrest and suppress transposable elements, notably inhibiting LINE-1.
- LINE-1-derived DNA can activate the cGAS-STING pathway, promoting cell cycle arrest and immune responses.
Conclusions:
- RTIs induce DNA strand breaks, incomplete retrotransposition, cell cycle arrest, and immune responses in cancer cells.
- The relationship between PARP1, PARP2, DNA methylation, and LINE-1 retrotransposition warrants further investigation.
- RT inhibitors like efavirenz show promise for preclinical evaluation as repurposed cancer drugs.
Related Concept Videos
Retrovirus Life Cycles
Mechanisms of Retrovirus-induced Cancers
Viruses with RNA Genomes
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Retroviruses
Size and Structure of Viral Genomes

